Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

41.23 -0.23 (-0.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,045,064
Open 41.33
Bid (Size) 41.23 (10)
Ask (Size) 41.27 (1)
Prev. Close 41.46
Today's Range 40.26 - 41.76
52wk Range 29.16 - 43.62
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 14.4% in the afternoon session after the company posted strong second-quarter earnings that beat expectations... 
Via StockStory
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2025 results topping the market’s revenue expectations, but sales fell by 1.7% year on year to $165.5 million. The... 
Via StockStory

Performance

YTD
+13.2%
+13.2%
1 Month
+26.2%
+26.2%
3 Month
+30.1%
+30.1%
6 Month
+7.4%
+7.4%
1 Year
+31.0%
+31.0%

More News

Read More
Supernus Announces Second Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For August 5, 2025
Via Benzinga
Supernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect
Via StockStory
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today
Via StockStory
Topics Lawsuit
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Via StockStory
Topics Artificial Intelligence Intellectual Property
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today
Via StockStory
Topics Artificial Intelligence Lawsuit
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) - An Undervalued Stock With Strong Fundamentals
Via Chartmill
1 Stock Under $50 with Exciting Potential and 2 to Turn Down
Via StockStory
2 Cash-Heavy Stocks to Own for Decades and 1 to Approach with Caution
Via StockStory
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms
Via Stocktwits
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics
Via Stocktwits
Topics Government
Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal
Via Benzinga
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million
Via Investor's Business Daily
Topics ETFs
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
From Supernus Pharmaceuticals, Inc.; Sage Therapeutics, Inc.
Via GlobeNewswire
3 Small-Cap Stocks Facing Headwinds
Via StockStory
1 Cash-Producing Stock for Long-Term Investors and 2 to Keep Off Your Radar
Via StockStory
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 41.23
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 08/08/25 04:00 PM ET
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.19B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.